AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 65% Vo2max
Number of subjects: 6
Study 1011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 82% Vo2max
Number of subjects: 6
Study 1011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at varying intensities
Number of subjects: 6
Study 31678425 — intervention group
Group type: EXPERIMENTAL
Intervention: adamgammadex sodium
Number of subjects: 52
Study 31678425 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study 31013872 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-live bifidobacteria (group H)
Number of subjects: 98
Study 31013872 — intervention group
Group type: EXPERIMENTAL
Intervention: Live bifidobacteria (group L)
Number of subjects: 98
Study 31013872 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group N)
Number of subjects: 98
Study 31013872 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups H and L to group N
Number of subjects: 98
Study 28706172 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching services (once a week for 8 weeks)
Number of subjects: 43
Study 28706172 — intervention group
Group type: COMPARATOR
Intervention: Home-visiting nursing services (once a week for 8 weeks)
Number of subjects: 43
Study 26050541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 or 0.5 mg)
Number of subjects: 483
Study 24262392 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual modeling (group I)
Number of subjects: 90
Study 24262392 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 90
Study 22093843 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM test (current infection marker kit, Genelabs Diagnostics)
Number of subjects: 300
Study 19508994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 257
Study 19508994 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 257
Study 17877887 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course, high-dose oral antiviral therapy (specific agents not detailed)
Number of subjects: 0
Study 17877887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral antiviral agents (aciclovir, valaciclovir, famciclovir) with topical corticosteroids
Number of subjects: 0
Study 17877887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir, valaciclovir, famciclovir
Number of subjects: 0
Study 17877887 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic therapy for minimally invasive procedures
Number of subjects: 0
Study 15791515 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy (1 treatment of >or=1 consecutive application at 50 degrees C for 30 s)
Number of subjects: 401
Study 15791515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional sodium stibogluconate (SSG) (5 injections of 2-5 mL every 5-7 days)
Number of subjects: 401
Study 15791515 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular sodium stibogluconate (SSG) (20 mg/kg daily for 21 days)
Number of subjects: 401
Study 15791515 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Number of subjects: 401
Study 15791515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional SSG
Number of subjects: 401
Study 11581504 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice schedule
Number of subjects: 36
Study 11581504 — intervention group
Group type: COMPARATOR
Intervention: Constant practice schedule
Number of subjects: 36
Study 11581504 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision of the effector present
Number of subjects: 36
Study 11581504 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision of the effector absent
Number of subjects: 36
Study 9855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmed screw
Number of subjects: 607
Study 9855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tronzo screw
Number of subjects: 607
Study 9855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ullevaal screw
Number of subjects: 607
Study 7978470 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hormone infusion (epinephrine, cortisol, glucagon)
Number of subjects: 12
Study 7978470 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 2919759 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 2919759 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study 31058797 — intervention group
Group type: COMPARATOR
Intervention: EXERCISE
Number of subjects: 24
Study 31058797 — intervention group
Group type: EXPERIMENTAL
Intervention: EXERCISE+PEH
Number of subjects: 24
Study 28750232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair yoga therapy (twice-weekly 20-min sessions for 12 weeks)
Number of subjects: 56
Study 28750232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair yoga therapy
Number of subjects: 56
Study 28750232 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 56
Study 25196993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab 180 mg every 4 weeks (Q4W)
Number of subjects: 120
Study 25196993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab 180 mg every 2 weeks (Q2W)
Number of subjects: 120
Study 25196993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab 270 mg every 2 weeks (Q2W)
Number of subjects: 120
Study 25196993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab (highest dose group)
Number of subjects: 120
Study 25196993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blosozumab
Number of subjects: 120
Study 25196993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23291970 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 1)
Number of subjects: 74
Study 23291970 — intervention group
Group type: COMPARATOR
Intervention: TAP block only (Group 2)
Number of subjects: 74
Study 23291970 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 3)
Number of subjects: 74
Study 21273183 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily orally until progression or inacceptable toxicity
Number of subjects: 0
Study 21273183 — intervention group
Group type: COMPARATOR
Intervention: Intermittent erlotinib and docetaxel (docetaxel 75 mg/m² on day 1 and erlotinib 150 mg orally on days 2‐16, recycled every 3 weeks up to 4 cycles, followed by erlotinib 150 mg daily until disease progression or inacceptable toxicity)
Number of subjects: 0
Study 21273183 — intervention group
Group type: COMPARATOR
Intervention: Intermittent erlotinib and docetaxel
Number of subjects: 0
Study 19448377 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL sucrose 24% with pacifier
Number of subjects: 36
Study 19448377 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL sterile water with pacifier
Number of subjects: 36
Study 16933589 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine added to usual treatment, attempted dosage of at least 400 mg daily.
Number of subjects: 19
Study 12814405 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent randomised trials in colorectal surgery
Number of subjects: 0
Study 11908489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) started within 2 hours preoperatively (Group A)
Number of subjects: 60
Study 11908489 — intervention group
Group type: COMPARATOR
Intervention: Intraaortic balloon pump (IABP) instituted intraoperatively (Group B)
Number of subjects: 60
Study 9578871 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPP impregnated ribbon gauze (Aurum)
Number of subjects: 0
Study 9578871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pope wicks (Xomed‐Teace)
Number of subjects: 0
Study 9578871 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic sheeting (Dow Corning)
Number of subjects: 0
Study 9578871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri‐adcortyl ointment (Squibb)
Number of subjects: 0
Study 9578871 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7699846 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (5 mg/kg)
Number of subjects: 73
Study 7699846 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (10 mg/kg)
Number of subjects: 73
Study 7699846 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup
Number of subjects: 73
Study 2529299 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant taste symptom in depressed patients
Number of subjects: 47
Study 2529299 — intervention group
Group type: COMPARATOR
Intervention: Previous drug treatment
Number of subjects: 47
Study 2529299 — intervention group
Group type: COMPARATOR
Intervention: Prognosis, severity or type of depression
Number of subjects: 47
Study 2529299 — intervention group
Group type: COMPARATOR
Intervention: Historical factors
Number of subjects: 47
Study 686922 — intervention group
Group type: EXPERIMENTAL
Intervention: COAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with cyclophosphamide)
Number of subjects: 274
Study 686922 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with daunorubicin)
Number of subjects: 274
Study 686922 — intervention group
Group type: EXPERIMENTAL
Intervention: OAP (vincristine, prednisone, cytarabine 200 mg/sq m/day)
Number of subjects: 274
Study 686922 — intervention group
Group type: COMPARATOR
Intervention: OAP (maintenance treatment)
Number of subjects: 274
Study 686922 — intervention group
Group type: COMPARATOR
Intervention: COAP (maintenance treatment)
Number of subjects: 274
Study 31764727 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited scheduling for interval tubal ligation
Number of subjects: 126
Study 31764727 — intervention group
Group type: COMPARATOR
Intervention: Standard scheduling for interval tubal ligation
Number of subjects: 126
Study 31764727 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited scheduling
Number of subjects: 126
Study 31764727 — intervention group
Group type: COMPARATOR
Intervention: Standard scheduling
Number of subjects: 126
Study 28579168 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated stent (DCS)
Number of subjects: 1564
Study 28579168 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1564
Study 26590128 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 100 mg
Number of subjects: 49
Study 26590128 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 500 mg
Number of subjects: 49
Study 26590128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23611248 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard task difficulty
Number of subjects: 3
Study 23611248 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium task difficulty
Number of subjects: 3
Study 23611248 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy task difficulty
Number of subjects: 3
Study 23611248 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3
Study 21767340 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily detemir at 50, 65 or 80% of IV insulin requirements and aspart according to carbohydrate intake
Number of subjects: 82
Study 21767340 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 82
Study 19420391 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activities done outside of school time
Number of subjects: 1925
Study 16896884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg adjuvant to radiotherapy
Number of subjects: 1370
Study 16896884 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1370
Study 15103483 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended clinical diagnostics with MRI and an expanded neuropsychological test battery (2000/2001)
Number of subjects: 343
Study 11756857 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy for 4 to 5 weeks
Number of subjects: 20
Study 11756857 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy for one year
Number of subjects: 20
Study 11756857 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual performance measures (visual acuity, contrast sensitivity, threshold perimetry)
Number of subjects: 20
Study 9008458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 44
Study 9008458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 44
Study 9008458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg
Number of subjects: 44
Study 9008458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg
Number of subjects: 44
Study 9008458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (all doses combined)
Number of subjects: 44
Study 9008458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9312340 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 90
Study 9312340 — intervention group
Group type: COMPARATOR
Intervention: Double blind placebo
Number of subjects: 90
Study 29860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg weekly
Number of subjects: 0
Study 29860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial responders (PRRs) receiving ADA
Number of subjects: 0
Study 30235984 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton (EB) CL
Number of subjects: 102
Study 30235984 — intervention group
Group type: COMPARATOR
Intervention: TightRope (TR) RT
Number of subjects: 102
Study 26452650 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid advancement of enteral feeding
Number of subjects: 83
Study 26452650 — intervention group
Group type: COMPARATOR
Intervention: Slow advancement of enteral feeding
Number of subjects: 83
Study 24214881 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DBP concentrations (Q4)
Number of subjects: 262
Study 24214881 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated free 25(OH)D (Q4 vs. Q1 of the 25(OH)D:DBP ratio)
Number of subjects: 262
Study 21967019 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 24
Study 21967019 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventionally treated)
Number of subjects: 24
Study 21033613 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (pedaled 50 minutes on a bicycle ergometry at 60% of maximal effort once a week for 12 weeks)
Number of subjects: 40
Study 21033613 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 40
Study 21033613 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 40
Study 17711537 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) tablets
Number of subjects: 0
Study 17711537 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial AUC
Number of subjects: 0
Study 17711537 — intervention group
Group type: EXPERIMENTAL
Intervention: C(max)
Number of subjects: 0
Study 16685862 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation method using a binary approximate kNN classifier followed by a three-class classifier for cartilage segmentation.
Number of subjects: 0
Study 12724679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infusion
Number of subjects: 21
Study 12724679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion
Number of subjects: 21
Study 12724679 — intervention group
Group type: COMPARATOR
Intervention: Historic controls (62 patients)
Number of subjects: 21
Study 10227333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% plus beclomethasone dipropionate nasal spray
Number of subjects: 533
Study 10227333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% alone
Number of subjects: 533
Study 10227333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 533
Study 10227333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined active therapy (ipratropium bromide plus beclomethasone)
Number of subjects: 533
Study 10227333 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (matching placebo nasal spray)
Number of subjects: 533
Study 8913958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein S deficiency
Number of subjects: 50
Study 8913958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C deficiency
Number of subjects: 50
Study 8913958 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III deficiency
Number of subjects: 50
Study 8913958 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen deficiency
Number of subjects: 50
Study 8913958 — intervention group
Group type: COMPARATOR
Intervention: Activated protein C ratio
Number of subjects: 50
Study 2057268 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (100 mg of phospholipid/kg)
Number of subjects: 798
Study 6681934 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin alone
Number of subjects: 78
Study 6681934 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus DDP
Number of subjects: 78
Study 6681934 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 78
Study 6681934 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stable disease
Number of subjects: 78
Study 6681934 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increasing disease
Number of subjects: 78
Study 30176281 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (100 mg/day)
Number of subjects: 30
Study 30176281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch, 100 mg/day)
Number of subjects: 30
Study 30075678 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Length Sequences (MLS)
Number of subjects: 6
Study 30075678 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Randomized Stimulation and Averaging (I‐RSA)
Number of subjects: 6
Study 30075678 — intervention group
Group type: EXPERIMENTAL
Intervention: Click level varied from 105 to 135 dB re: 1 μPa at rates from 100 to 1000 Hz
Number of subjects: 6
Study 26459373 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 465
Study 26459373 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 465
Study 25111109 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise (60-minute sessions, twice per week for 8 weeks)
Number of subjects: 60
Study 25111109 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 60
Study 23176882 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine (TIV) administered using a 2-step approach (0.1 mL followed by full dose if no reaction)
Number of subjects: 31
Study 23176882 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) followed by full dose of TIV if no reaction
Number of subjects: 31
Study 23176882 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of TIV
Number of subjects: 31
Study 23176882 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose of TIV
Number of subjects: 31
Study 19796383 — intervention group
Group type: EXPERIMENTAL
Intervention: fibre-enriched milk drink
Number of subjects: 26
Study 19796383 — intervention group
Group type: COMPARATOR
Intervention: lactose-free milk drink
Number of subjects: 26
Study 19796383 — intervention group
Group type: COMPARATOR
Intervention: normal fat-free milk
Number of subjects: 26
Study 17618805 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy simulator training (treatment group)
Number of subjects: 24
Study 17618805 — intervention group
Group type: COMPARATOR
Intervention: No additional training (control group)
Number of subjects: 24
Study 15167948 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 100
Study 11600822 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose Nevirapine (NVP)
Number of subjects: 111
Study 9702286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (divalproex sodium; Depakote)
Number of subjects: 37
Study 9702286 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 37
Study 8045951 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (DEX)
Number of subjects: 11
Study 8045951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2498025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30
Study 2498025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 30
Study 2498025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 30
Study 2498025 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine response
Number of subjects: 30
Study 2498025 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine vs Tocainide
Number of subjects: 30
Study 31601716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Hypoglossal Nerve Stimulation (HNS) using the Genio™ system
Number of subjects: 27
Study 28854571 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention providing personalized normative feedback and general information about alcohol
Number of subjects: 1147
Study 28854571 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to a consumption diary only
Number of subjects: 1147
Study 28854571 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 1147
Study 26184649 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 1013
Study 26184649 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1013
Study 23294870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 120
Study 23294870 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin-metronidazole combined therapy
Number of subjects: 120